1. |
- Moberg, Christina, et al.
(författare)
-
De unga gör helt rätt när de stämmer staten
- 2022
-
Ingår i: Aftonbladet. - 1103-9000.
-
Tidskriftsartikel (populärvet., debatt m.m.)abstract
- 1 620 forskare och lärare i forskarvärlden: Vi ställer oss bakom Auroras klimatkrav
|
|
2. |
- Andersson, Åsa, Professor, 1960-, et al.
(författare)
-
Serum Protein Response To A Single High-Intensity Interval Training Bout – Comparison Between Individuals With Spondyloarthritis And Healthy Controls
- 2022
-
Ingår i: Annals of the Rheumatic Diseases. - London : BMJ Publishing Group Ltd. - 0003-4967 .- 1468-2060. ; 81:Suppl 1, s. 780-781
-
Tidskriftsartikel (refereegranskat)abstract
- Axial spondyloarthritis (axSpA) is a chronic inflammatory disease affecting mainly the axial skeleton. To decrease the risk of cardiovascular comorbidity, aerobic training is recommended as a part of disease management in patients with axSpA. High-intensity interval training (HIIT) interventions are, in addition to other recommended treatments, believed to positively affect the disease activity (1). However, the knowledge about the acute effects of HIIT on the inflammatory process at the molecular level is less studied. Understanding the acute HIIT effects on cytokines and additional serum proteins in axSpA is important for further long-term HIIT interventions and recording of the effect of HIIT on the axSpA disease profile.ObjectivesTo study the acute effects on serum proteins, such as cytokines, myokines, and inflammatory- and bone-related proteins, in response to a single bout of HIIT, and to compare the levels between baseline and post-HIIT in patients with axSpA and healthy controls (HC).MethodsThe pilot study included twenty-one participants (10 female, 11 male), mean (SD) age 40 (7) years, ten with axSpA, and eleven age and sex matched HC, who performed a single HIIT on a cycle ergometer consisting of 4x4 minutes interval (90% heart rate, HR-max) with three minutes active rest in between (70% of HR-max). Disease activity (BASDAI, 0-10) in patients with axSpA was 1.6 (0.8). Health status EuroQol (EQ5D, 0-1) were 0.87 (0.11) for axSpA, and 0.93 (0.10) for HC. The groups were well matched with no difference in baseline data for weight, BMI, EQ5D, blood pressure or aerobic capacity.Blood samples were taken before (baseline) and one hour after the single HIIT. The following serum proteins were analyzed on a Luminex MAGPIX System (Luminex corporation, Austin, TX USA): Interleukin (IL)-6, IL-17, IL-18, TNFαAGPIX System (Luminex corporatiosteoprotegerin, osteocalcin, osteopontin, and FGF-23. A three-way analysis of variance (ANOVA) was used to detect differences between groups, between sexes, and before and after a HIIT bout in a 2(group)*2(sex)*2(time) design. For main effects or interactions significant at p≤0.05, simple effect t-tests were used to determine the specific effects.ResultsA group main effect (p=0.048) showed that the serum level of IL-6 was increased one hour after the HIIT session primarily in the HC, 0.4 pg/ml (SD±0.4) at baseline vs. post-HIIT 1.8 (2.0). The concentration of the cytokines/chemokine IL-17, IL-18, TNFα group main effect (p=0.048) showed that the serum level of IL-6 was increased one hour after the HIIT session primarily in30) in VEGF-A showed that the axSpA group had significantly lower VEGF-A at baseline, 159 pg/ml (138) vs 326 (184) in the control group (which might be due to anti-inflammatory medication). A sex main effect (p=0.029) was observed from baseline to post-HIIT for the bone hormone osteocalcin, with a more pronounced decrease of serum osteocalcin in women with axSpA, 14.0 ng/ml (8.3) vs. post HIIT 13.2 (6.9). Moreover, the level of the multifunctional protein osteopontin was significantly lower (sex main effect, p=0.021) in women, 10.7 ng/ml (7.0) vs. men 20.4 (10.1), post-HIIT.ConclusionThis pilot study shows that one bout of HIIT influences the expression of proteins involved in inflammation and metabolism, and that sex is an important factor in the response to HIIT. The results should be followed up in longer intervention studies including higher numbers of participants.References[1]Sveaas, S. H. et al. (2019). High intensity exercise for 3 months reduces disease activity in axial spondyloarthritis (axSpA): a multicentre randomised trial of 100 patients. British journal of sports medicine, 54(5), 292-297.Disclosure of InterestsÅsa Andersson: None declared, Emma Haglund Consultant of: Novartis, Emma Berthold: None declared, Elisabeth Mogard Consultant of: Novartis, Anna Torell: None declared, M Charlotte Olsson: None declared
|
|
3. |
|
|
4. |
|
|
5. |
- Olsson Månsson, Emma, 1992, et al.
(författare)
-
Removal of Inorganic Impurities in the Fast Pyrolysis Bio-oil Using Sorbents at Ambient Temperature
- 2024
-
Ingår i: Energy & Fuels. - 1520-5029 .- 0887-0624. ; 38:1, s. 414-4254
-
Tidskriftsartikel (refereegranskat)abstract
- Fast pyrolysis bio-oil (FPBO) sourced from residual biomass waste (such as sawdust) is a promising feedstock that may be used for biofuel production. Their inorganic elements may, however, vary and cause deactivation of the catalysts in the hydrodeoxygenation (HDO) upgrading biorefinery unit. It was found that the use of zeolite Y and strong acidic ion-exchange resins as adsorbents was almost equally efficient in lowering the concentrations of Ca from <10 to <1 ppm and of Fe, K, and Mg to <0.3 ppm in FPBO at 30 °C, atmospheric pressure, and 4 h adsorption time. The removal efficiency of zeolite and resins exceeded 85–98% (detection limit) of these particular elements. For the first time for the FPBO, phosphorus was reported as being successfully targeted by aluminum oxide, being lowered from 1 ppm to <0.1 ppm, which is a reduction of at least 90%. Characterization of the oil and sorbents suggests that the surface acidity affects the removal efficiency of these elements from FPBO. Organic compounds in the pyrolysis oil, including isopropanol, lactic acid, hydroxy acetone, furfural, guaiacol, and levoglucosan, were semiquantified using two-dimensional gas chromatography coupled with mass spectrometry (GCxGC-MS). Compared to the fresh oil, the compositions and contents of these organic compounds were not impacted significantly by the sorbents under these mild operating conditions. This research indicates that inorganic impurities present in bio-oils can be removed, and thus, they may be considered feedstocks for producing biofuels with less deactivation of HDO catalysts.
|
|
6. |
|
|
7. |
- Ahlm, Emma, 1982-
(författare)
-
EU Law and Religion : A Study of How the Court of Justice has Adjudicated on Religious Matters in Union Law
- 2020
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- This study has caught a legal development in the making. The Court of Justice has, over the last ten years, developed a body of case law relating to religious matters in connection to EU law which spans a wide range of subject areas; non-discrimination law, data protection, state aid, animal welfare and slaughter rules. Historically, religion in Europe had strong ties to the nation state. The European Court of Human Rights has, in its interpretation of Article 9 ECHR, upheld European supervision of religious freedom in the contracting states. However, due to the lack of European consensus concerning the relationship between state and religion, the Court of Human Rights has left a wide margin of appreciation to the state. The question this study answers is whether the Court of Justice has left a similar margin of discretion to the Member States in its adjudication on religious matters.By analysing the development over the last ten years, one can discern an EU law on religion which is independent from the Court of Human Rights, and from the Member States. An "EU law on Religion" includes the general principle of religious equality – in Article 21 CFR – and religious freedom – in Article 10 CFR, applied in a uniform way, but also limits of the secular jurisdiction of the Court of Justice and the neutrality of the Union. Although the Union has limited competence in legislating on religious matters in the Member States, it does not hinder Union law from impacting the Member States, since they must organize their relationship to religious matters in conformity with Union law. Article 17(1) TFEU states that the Union shall respect the status of churches and religious organizations under national law, but this article has not been interpreted by the Court of Justice as safeguarding the traditions of the Member States. In contrast, this study advances an understanding of Union law greatly relevant to religion in the Member States.
|
|
8. |
|
|
9. |
- Andersson, Gerhard, Professor, 1988-, et al.
(författare)
-
Individually tailored Internet-delivered cognitive-behavioral therapy for survivors of intimate partner violence : A randomized controlled pilot trial
- 2021
-
Ingår i: Internet Interventions. - : Elsevier BV. - 2214-7829. ; 26
-
Tidskriftsartikel (refereegranskat)abstract
- Intimate partner violence (IPV) is a serious public health concern worldwide and defined as behavior performed by spouses or other intimate partners that causes physical, sexual, or psychological harm. Internet-delivered cognitive-behavioral therapy (ICBT) may be particularly useful for survivors of IPV for several reasons, including barriers pertaining to limited community recourses and treatment availability, safety concerns, and issues of stigma, guilt and shame, which may prevent members of this population from seeking help via face-to-face interactions. However, Internet interventions are lacking. The primary aim of the present randomized controlled pilot trial was to explore the feasibility of ICBT as guided self-help individually tailored to the predominant symptomatology of PTSD or depression in survivors of IPV. A second aim was to conduct a preliminary evaluation exploring the short- and long-term effects of the treatment in comparison to a waitlist control condition. Results showed that the treatment was feasible. Attrition rate was low (9.4%), and participants were satisfied with treatment. However, treatment adherence was moderate in terms of completed modules (62.5%). Results of the preliminary evaluation of treatment effects showed large and statistically significant between-group effect sizes (Cohen's d = 0.86–1.08) on some measures of PTSD and depression at post assessment, favoring the treatment condition. However, there were no effects on other measures. At follow-up assessment, when the control condition had received delayed treatment, there were large and statistically significant within-group effect sizes (d = 0.96–1.48) on measures of PTSD, depression and anxiety, and small effects (d = 0.48) on a measure of quality of life. The results of the present pilot study are promising and warrant further research on ICBT for this population.
|
|
10. |
- Axfors, Cathrine, et al.
(författare)
-
Association between convalescent plasma treatment and mortality in COVID-19 : a collaborative systematic review and meta-analysis of randomized clinical trials
- 2021
-
Ingår i: BMC Infectious Diseases. - : BioMed Central (BMC). - 1471-2334. ; 21:1
-
Forskningsöversikt (refereegranskat)abstract
- Background: Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, ). Methods: In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung-Knapp-Sidik-Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. Results: A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I-2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. Conclusions: Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care.
|
|